Preliminary Results from the St. Jude Medical EnligHTN III Study Demonstrate Renal Denervation is Safe and Effective
Results from the EnligHTN I, II and III trials presented during EuroPCR add to the growing body of clinical evidence supporting the benefits of EnligHTN renal denervation technologies
ST. PAUL, Minn. and PARIS – May 22, 2014 – St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced preliminary results from the EnligHTN III study, which found the company’s second-generation EnligHTN™ renal denervation system provided safe and effective therapy for patients with drug-resistant, uncontrolled hypertension six months post-procedure. The results were presented during a hot line late-breaking clinical trial session at EuroPCR 2014.
The EnligHTN III study is an international, non-randomized clinical trial that followed device performance and assessed outcomes through six months of follow-up for 39 eligible patients. Preliminary results confirmed safe, rapid and sustained reduction in blood pressure measurements for patients with drug-resistant hypertension, meaning their high blood pressure could not be controlled through medication.
“This six-month data from EnligHTN III provides further evidence of the benefits associated with this next-generation renal denervation system,” said Prof. Stephen Worthley of St. Andrew's Hospital in Adelaide, Australia, a principal investigator of the EnligHTN III study. “This study demonstrates that the next-generation EnligHTN renal denervation system delivers safe and effective treatment that is aligned with the outcomes of the first generation system, and ultimately saves time in the procedure room.”
Six-month EnligHTN III data showed:
An average systolic blood pressure reduction of 25 mmHg points
81 percent of patients responded to the therapy, which is defined as a blood pressure reduction of at least 10 mmHg when measured during an office visit
No serious device- or procedure-related adverse events reported
EnligHTN I and EnligHTN II Data
The EnligHTN III study expands upon the research conducted in the EnligHTN I trial of the first-generation EnligHTN system, which demonstrated that patients with drug-resistant hypertension had a safe drop in blood pressure. New data from the
EnligHTN I trial, presented at EuroPCR 2014, confirmed the fast, early reduction in blood pressure remains sustained at 24 months, further demonstrating the long-term benefits of this procedure when using the EnligHTN technology. 77 percent of patients were responders at 24 months, with a blood pressure reduction of at least 10 mmHg.
St. Jude Medical, Inc.
Forty-six patients were treated with the EnligHTN system in the EnligHTN I multicenter study. To be considered for enrollment, patients were required to have a systolic blood pressure above 160 mmHg (150 mmHg for patients with type II diabetes) and take at least three antihypertensive medications, including a diuretic. Notably, the EnligHTN I study reports the longest term follow-up to date on a multi-electrode ablation catheter.
Also presented at EuroPCR were one-month findings from the post-market EnligHTN II clinical trial. Preliminary results demonstrated a reduction in systolic blood pressure across sub-groups with varying degrees of hypertension and kidney functionality, and found an early 14 mmHg reduction in blood pressure in patients with a systolic blood pressure above160 mmHg. Blood pressure reduction for patients with a systolic blood pressure above 160 mmHg was in-line with previous real-world, post market studies. While still reporting a reduction, patients with poor kidney functionality and a baseline blood pressure lower than 160 mmHg did not have as large of a reduction of blood pressure at one month.
The EnligHTN II trial is being conducted at up to 40 sites in Europe and Australia and will enroll up to 500 patients with uncontrolled hypertension. The data presented during EuroPCR was from 18 centers and 100 patients.
Collectively, the EnligHTN trials are approaching 300 treated patients with ongoing enrollments in the EnligHTN II trial and observational registries across Europe and Australia.
“St. Jude Medical is encouraged by the positive clinical results we’re seeing from our renal denervation studies,” said Dr. Mark D. Carlson, chief medical officer for St. Jude Medical. “We have a long history of advancements in ablation technologies and have used our internal product development capabilities to optimize our multi-electrode renal denervation technology. We believe this therapy has the potential to dramatically improve the lives of millions of patients with severe high blood pressure and will continue to invest in renal denervation as a potential long-term growth driver.”
Renal denervation is a catheter-based ablation procedure used to treat patients with drug-resistant hypertension (high blood pressure). The EnligHTN system delivers radiofrequency (RF) energy from an ablation catheter to create lesions (tiny scars) along the renal nerves – a network of nerves in the walls of the renal arteries thought to help control blood pressure. The intentional disruption of the nerve supply has been clinically found to help reduce systolic and diastolic blood pressure. The catheter has a unique, non-occlusive basket design, helping physicians deliver a predictable treatment pattern while allowing for continuous blood flow to the kidney throughout the procedure.
Blood pressure reduction is quickly achieved by simultaneously administering 60 second ablations from all four catheter electrodes, which is typically performed two times in each renal artery. The next-generation EnligHTN system offers physicians a multi-electrode catheter with an intuitive, faster generator that quickly and effectively delivers consistent ablations with a significant reduction in procedure time.
Senior Client Executive | Racepoint Global
Connect with us:
Boston • Washington DC • San Francisco • London • Beijing • Shanghai • Hong Kong
Thursday, May 22, 2014